The psilocybin mushroom story is in the early stages of a multi-year boom. In fact, we’re already seeing a groundswell of interest, as mushrooms become a promising candidate for anxiety and depression because it “appears to disrupt the sorts of engrained brain activity patterns that are the hallmark of those diseases,” says Business Insider. That news holds sizable promise for companies, such as The Yield Growth Corp. (CSE:BOSS)(OTC:BOSQF).
Other studies are looking at psilocybin mushroom’s effect on anxiety, PTSD, and alcoholism.
For example, researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.
“Theoretically, psilocybin helps “loosen” the deeply-rooted patterns of thinking and behavior behind many of these mental disorders, according to King’s College London, as highlighted by CNN. “It could ‘relax’ the parts of our brain that control these behaviors, thus allowing old patterns to change or fade. Patients who have received psilocybin have described coming down from the high with “new insights” and changed perspectives on their difficulties.”
READ MORE HERE: www.baystreet.ca/articles/stockstowatch/53620/Psilocybin-Mushrooms-Becoming-One-of-the-Hottest-Investment-Stories-of-2020